gdc

Leukemia

Cytogenetic Testing in Chronic Lymphocytic Leukemia
Leukemia
Cytogenetic testing is used to identify genomic aberrations in patients with chronic lymphocytic leukemia (CLL). It estimates a patient’s outcomes and can predict response to certain therapies, and therefore is recommended for all patients with CLL at diagnosis.
Acalabrutinib Alone or in Combination More Effective than Chemoimmunotherapy in Previously Untreated CLL
Leukemia
A new study presented at a major medical meeting showed that fewer patients with treatment-naïve chronic lymphocytic leukemia (CLL) who were treated with acalabrutinib alone or in combination with obinutuzumab had disease progression or died compared with a group of patients treated with the combination of obinutuzumab and chemotherapy.
Triplet Regimen with Acalabrutinib Is Highly Active in Untreated Chronic Lymphocytic Leukemia
Leukemia
A 3-drug regimen of acalabrutinib, venetoclax, and obinutuzumab was highly effective in removing all traces of disease from the bone marrow of patients with chronic lymphocytic leukemia, according to study results presented at the American Society of Hematology annual meeting.
Information Is Power: Targeted Therapies Extend Survival for Patients with Chronic Lymphocytic Leukemia
Leukemia
Until recently, the initial treatment for patients with CLL was chemotherapy alone. New targeted therapies are now available for use as the first treatment for CLL. At the 2019 ASCO meeting, 2 experts discussed the benefits of these new treatments.
Tibsovo Approved for First-Line Treatment of Patients with Acute Myeloid Leukemia and IDH1 Mutation
FDA Approvals, News & UpdatesLeukemia
In May 2019, the FDA approved Tibsovo for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) and an IDH1 mutation, or for patients with AML who are unable to use intensive chemotherapy.
Several Chemo-Free Combination Therapies Now Available for Patients with Chronic Lymphocytic Leukemia
Leukemia
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults. Recently, several new drug combinations without chemotherapy have been approved by the FDA for patients with CLL, providing patients new options when their cancer stops responding to current treatment.
There’s No Place Like Home: How a Visit to the United States Saved My Life
Financial SupportLeukemiaPatient Stories
Martin Miralda was fresh out of college when a short visit to the United States helped to save his life after he was diagnosed with leukemia. Despite his lacking health insurance as a non-resident, he received superior medical care through “Charity Care,” a service that covers necessary hospitalization for uninsured people in the country and is available in several states.
Imbruvica as First Treatment a New Standard in Older Patients with Chronic Lymphocytic Leukemia
Leukemia
Results of a recent study showed that using the targeted therapy Imbruvica (ibrutinib) as the first treatment in older adults with CLL was better than the combination of chemotherapy plus immunotherapy in slowing the progression of the disease.
FDA Approves Imbruvica plus Gazyva for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
FDA Approvals, News & UpdatesLeukemia
This new chemotherapy-free combination of Imbruvica, a targeted therapy, plus Gazyva, a CD20-directed cytolytic antibody, was recently approved by the FDA as first-line treatment of adults aged 65 or older who are newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Telling Patients About CAR T-Cell Therapy
ImmunotherapyLeukemiaLymphomaPersonalized Medicine
Nurse Navigator Claire White describes the way she tells her patients what CAR T-cell therapy is and how it works.
Page 4 of 7
Results 35 - 44 of 62

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country